title: Neuroleptic malignant syndrome.
abstract: Neuroleptic malignant syndrome (NMS) is a potentially fatal adverse event associated with the use of antipsychotics (AP). The objective of this study was to investigate the profile of cases of NMS and to compare our findings with those published in similar settings. A series of 18 consecutive patients with an established diagnosis of NMS was analyzed, gathering data on demography, symptoms and signs. Two thirds of all cases involved woman with a past medical history of psychiatric disorder receiving relatively high doses of AP. The signs and symptoms of NMS episodes were similar to those reported in other series and only one case had a fatal outcome, the remaining presenting complete recovery. As expected, more than two thirds of our cases were using classic AP (68%), however the clinical profile of these in comparison with those taking newer agent was similar. Newer AP also carry the potential for NMS.
authors: Department of Neurology, Pontifical Catholic University of Paraná, Curitiba, PR, Brazil.
authors: Mariana
authors: M
authors: Moscovich
authors: Felipe T M
authors: FT
authors: Nóvak
authors: Artur F
authors: AF
authors: Fernandes
authors: Tatiana
authors: T
authors: Bruch
authors: Tabita
authors: T
authors: Tomelin
authors: Edison M
authors: EM
authors: Nóvak
authors: Renato P
authors: RP
authors: Munhoz
authors: Hélio A G
authors: HA
authors: Teive
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000009:adverse effects*; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis* / Q000209:etiology; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents